title: Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
abstract: Neuroendocrine (NE) differentiation in prostate cancer (CaP) has been reported to be an early marker associated with the development of androgen independence. The mechanisms by which CaP acquires NE properties are poorly understood. In this study, a putative role of adrenomedullin (AM) in the NE differentiation was investigated. The expression of AM and AM receptors (calcitonin receptor-like receptor (CRLR)/receptor activity modifying protein-2 and -3 (RAMP2 and RAMP3) was evaluated after experimental manipulation of androgen status. Levels of AM mRNA and immunoreactive AM (ir-AM) increased four- to sevenfold in androgen-sensitive LNCaP cells after androgen withdrawal in vitro and in LNCaP xenografts in animals after castration. Treatment of LNCaP cells with androgen analogue (dihydrotestosterone; 10(-9) M) prevented the increase in AM mRNA and ir-AM levels. Interestingly, the expression of CRLR, RAMP2 and RAMP3 is not regulated by androgen status. We demonstrate that in the presence of serum, AM is able to induce an NE phenotype in LNCaP cells via CRLR/RAMP2 and RAMP3, which includes extension of neuritic processes and expression of the neuron-specific enolase (NSE), producing cGMP in a dose-dependent manner, which is mediated by a pertussis toxin-sensitive GTP-binding protein. 8-Bromo-cGMP mimicked the effects of AM on cell differentiation. We demonstrate that AM induces a G-kinase Ialpha translocation to the nucleus. The protein kinase G inhibitor KT-5823 inhibited the neurite outgrowth induced by both AM and 8-bromo-cGMP. In noncastrated animals, administration of AM enhanced expression of NSE and chromogranin A in LNCaP xenografts with a significant increase of NSE levels in serum and no changes in tumor growth. In castrated animals, intraperitoneal injection of AM resulted in a 240+/-18% (P<0.001) increase in tumor volume 36 days after treatment, indicating that the nature of effect of AM in CaP depends on the presence or absence of endogenous androgen. Together, these results demonstrate that AM may function as a mediator of NE-like differentiation in culture as well as in vivo and indicate that its production may be important for tumor resurgence following androgen ablation.
authors.affiliation: Inserm E 359, Marseille, France.
authors.forename: C
authors.initials: C
authors.lastname: Berenguer
authors.forename: F
authors.initials: F
authors.lastname: Boudouresque
authors.forename: C
authors.initials: C
authors.lastname: Dussert
authors.forename: L
authors.initials: L
authors.lastname: Daniel
authors.forename: X
authors.initials: X
authors.lastname: Muracciole
authors.forename: M
authors.initials: M
authors.lastname: Grino
authors.forename: D
authors.initials: D
authors.lastname: Rossi
authors.forename: K
authors.initials: K
authors.lastname: Mabrouk
authors.forename: D
authors.initials: D
authors.lastname: Figarella-Branger
authors.forename: P-M
authors.initials: PM
authors.lastname: Martin
authors.forename: L'Houcine
authors.initials: L
authors.lastname: Ouafik
mesh_terms: D053607:Adrenomedullin / Q000235:genetics / Q000378:metabolism / Q000502:physiology* / Q000627:therapeutic use; D000728:Androgens / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D019898:Autocrine Communication / Q000187:drug effects / Q000502:physiology; D014408:Biomarkers, Tumor / Q000032:analysis; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy / Q000473:pathology*; D002454:Cell Differentiation; D049109:Cell Proliferation / Q000187:drug effects; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000473:pathology; D019899:Paracrine Communication / Q000187:drug effects / Q000502:physiology; D010641:Phenotype; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D058265:Receptors, Adrenomedullin; D018000:Receptors, Peptide / Q000235:genetics; D014407:Tumor Cells, Cultured; D028761:Withholding Treatment; D023041:Xenograft Model Antitumor Assays
chemical_list: D000728:Androgens; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D058265:Receptors, Adrenomedullin; D018000:Receptors, Peptide; D053607:Adrenomedullin